AP

Change at the top for Biogen after Alzheimer’s drug flops

May 3, 2022, 4:39 AM | Updated: 10:57 am

Biogen will replace its CEO and largely abandon marketing of its controversial Alzheimer’s drug Aduhelm less than a year after the medication’s launch triggered a backlash from experts, doctors and insurers.

CEO Michel Vounatsos will continue to lead the Biogen until a successor is found, the company announced Tuesday. Vounatsos joined the company in 2016 and was the chief architect of Biogen’s strategy built around Aduhelm.

For now, Biogen said it is “substantially eliminating” spending on Aduhelm as part of a $1 billion dollar cost-saving plan designed to refocus the company’s flagging biotech business.

The announcement represents a stark acknowledgement that the Cambridge, Massachusetts-based company has failed to find a market for a drug that was expected to drive its business for years to come.

Aduhelm was the first new Alzheimer’s drug introduction in nearly two decades. Initially priced at $56,000 a year, analysts predicted it would quickly become a blockbuster drug that would generate billions for Biogen.

But doctors have been hesitant to prescribe it, given weak evidence that the drug slows the progression of Alzheimer’s. Insurers have blocked or restricted coverage over the drug’s high price tag and uncertain benefit. Even the company’s decision to slash the drug’s price in half– to $28,000 a year — did little to improve uptake.

The biggest setback came last month when the federal government’s Medicare health plan imposed strict limits on who can get the drug, wiping out most of its potential U.S. market. The vast majority of U.S. Alzheimer’s patients are old enough to qualify for Medicare, which covers more than 60 million people, including those 65 and older.

The infused drug brought in just $2.8 million in sales in the first quarter, which ended March 31.

Biogen said Tuesday that it booked about $275 million in charges from Aduhelm inventory write-offs in the quarter, and it would essentially shutdown its sales and marketing infrastructure supporting the drug.

Aduhelm expenses dragged down the company’s quarterly results and Biogen fell short of Wall Street projections, reporting adjusted net income of $535 million, or $3.62 per share. Analysts forecast earnings of $4.34 per share, according to FactSet.

Biogen executives said the restrictive Medicare decision essentially denied Aduhelm to most eligible U.S. patients. Last month the company announced it was pulling its marketing application for the drug in Europe.

Biogen will continue running a federally-mandated confirmatory trial designed to establish if the drug truly slows Alzheimer’s.

The drugmaker’s quarterly revenue fell 6% to $2.5 billion, pressured by lower sales of multiple sclerosis drugs in the U.S. due to cheaper, generic competition. The company also reported lower sales of its specialty drug Spinraza, which is used to treat a rare spinal disorder in children.

For the year, Biogen reaffirmed earnings guidance of between $14.25 and $16.00 per share.

Biogen executives said they will continue pursuing new Alzheimer’s treatments including a drug similar to Aduhelm. Researchers are awaiting last-stage testing results for the drug in the fall. But the company also highlighted other drugs in its pipeline, including potential treatments for depression and schizophrenia.

Vounatsos departure was expected “given the many setbacks the company has faced,” RBC Capital Markets analyst Brian Abrahams wrote Tuesday. The move and reorganization “will be well received over the long term, and give the company a fresh start in refocusing R&D priorities.”

Shares of Biogen Inc. rose less than 1%.

Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

AP

FILE - Members of the Henderson Fire Department load Deb Billet, 66, into an ambulance before trans...

Associated Press

Things to know about heat deaths as a dangerously hot summer shapes up in the western US

A dangerously hot summer is shaping up in the U.S. West, with heat suspected in dozens of recent deaths.

13 hours ago

FILE - Dr. Ruth Westheimer participates in the "Ask Dr. Ruth" panel during the Hulu presentation at...

Associated Press

Dr. Ruth Westheimer, the sex therapist who became a pop icon, has died

Dr. Ruth Westheimer, the sex therapist who became a pop icon, media star and best-selling author, has died.

17 hours ago

Biden proposes rule to protect 36 million workers from extreme heat...

Associated Press

Biden proposes new rule to protect 36 million workers from extreme heat

President Joe Biden on Tuesday proposed a new rule to address excessive heat in the workplace, warning — as tens of millions of people in the U.S. are under heat advisories — that high temperatures are the country's leading weather-related killer.

11 days ago

FILE - Rori Chang, of Glendale, Ariz., walks with her dog Ava as they leave the Maricopa Country An...

Associated Press

Here are ways that can help ease dogs’ July Fourth dread

Those with furry, four-legged family members will be searching for solutions to the Fourth of July anxiety that fireworks bring.

12 days ago

Fossilized crocodilian excrement is displayed at the "Poozeum", Friday, June 7, 2024, in Williams, ...

Associated Press

Museum in northern Arizona tells stories of ancient animals through their fossilized poop

The Poozeum opened in May in Williams, a northern Arizona town known for its Wild West shows along Route 66.

12 days ago

walgreens-closures...

Associated Press

Walgreens to take a hard look at underperforming stores, could shutter hundreds more

Walgreens is finalizing a plan to fix its business that could result in the closure of hundreds of additional stores in the next three years.

16 days ago

Sponsored Articles

...

Midwestern University

Midwestern University Clinic visits boost student training & community health

Going to a Midwestern University Clinic can help make you feel good in more ways than one.

...

Collins Comfort Masters

Here’s how to be worry-free when your A/C goes out in the middle of summer

PHOENIX -- As Arizona approaches another hot summer, Phoenix residents are likely to spend more time indoors.

...

DESERT INSTITUTE FOR SPINE CARE

Desert Institute for Spine Care is the place for weekend warriors to fix their back pain

Spring has sprung and nothing is better than March in Arizona. The temperatures are perfect and with the beautiful weather, Arizona has become a hotbed for hikers, runners, golfers, pickleball players and all types of weekend warriors.

Change at the top for Biogen after Alzheimer’s drug flops